Quarterly ResultMay 14, 2026, 08:02 AM
CorMedix Q1 Revenue $127.4M, Net Income $38.6M; REZZAYO Phase III Positive
AI Summary
CorMedix Inc. reported a significant increase in total revenue to $127.4 million for Q1 2026, up from $39.1 million in Q1 2025, primarily driven by the Melinta Therapeutics acquisition in August 2025. Net income also rose to $38.6 million, or $0.43 diluted EPS, compared to $20.6 million, or $0.30 diluted EPS, in the prior year. The company also announced positive Phase III topline results for REZZAYO for prophylaxis of invasive fungal diseases, targeting commercialization in 2027. Additionally, a change in accounting estimates positively impacted net sales by $9.0 million and net income by $6.2 million.
Key Highlights
- Total Revenue increased to $127.4 million in Q1 2026 from $39.1 million in Q1 2025.
- Net Income rose to $38.6 million in Q1 2026 from $20.6 million in Q1 2025.
- Diluted EPS was $0.43 in Q1 2026, up from $0.30 in Q1 2025.
- Announced positive Phase III topline results for REZZAYO for prophylaxis of invasive fungal diseases.
- Cash and cash equivalents were $178.1 million as of March 31, 2026.
- Net cash provided by operating activities was $42.4 million in Q1 2026.
- Change in accounting estimates positively impacted net sales by $9.0 million.
- Binding settlement term sheet signed for one derivative legal action.
Price Impact
More from CRMD